Pramlintide

DB01278ApprovedInvestigationalSmall moleculeAmylin Analog

Pramlintide is an amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal.

Mechanism: Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.
Curator reviewed
Primary indication: For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.Curator reviewed · 2 structured indications
Formula / weight: C₁₇₁H₂₆₇N₅₁O₅₃S₂ · 3949.44 g/mol (avg)
First approval: United States, 2005
Code names: AC-0137 · AC-137
Brand names: Symlin

Resolves to

Compound

UNIID3FM8FA78TCAS151126-32-8ChEMBLCHEMBL2103758ChEBI135922KEGGD05595

Clinical / RWD

RxNorm139953ATCA10BX05PharmGKBPA164781394

Structure

InChIKeyTZIRZGBAFTZREM-MKAGXXMWSA-NSMILES

[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](C)NC(=O)[C@@]([H])(NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O

Targets

P30988CALCRO60894RAMP1O60895RAMP2O60896RAMP3P43220GLP1R

What you can answer from here — as of September 13, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

710Drug interactionsStructured to mechanism, not free text

34Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

6Marketed productsAcross 1 country and 3 labellers

1ATC codeIncluding every combination product, plus 15 drug categories

27+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pramlintide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account